Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CA102
- Development stage
- Preclinical
- Lead developer
- Curigin
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravesical
01
Overview
CA102 is a genetically engineered oncolytic adenovirus being developed by Curigin for the treatment of bladder cancer. The therapy integrates viral oncolysis with RNA interference (RNAi) technology to simultaneously inhibit two critical oncogenic pathways: Signal Transducer and Activator of Transcription 3 (STAT3) and Mechanistic Target of Rapamycin (mTOR). By blocking these pathways, CA102 aims to disrupt the genetic signaling required for tumor growth and survival. Currently in preclinical development, the program is supported by a manufacturing partnership with Charles River for adenoviral vector production, with plans to submit an Investigational New Drug (IND) application to the FDA.
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on CA102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CA102.